BioGaia AB is a pioneer in microbiome research, specializing in the development and commercialization of probiotic products based on the Limosilactobacillus reuteri (L. reuteri) bacterial strains. The company operates through three main segments: Pediatrics, Adult Health, and Other. The Pediatrics segment, which accounts for approximately 80% of total sales, offers products such as probiotic drops, oral rehydration solutions, and gut health tablets, as well as cultures used as ingredients in infant formula. The Adult Health segment (around 20% of sales) provides gut health tablets, bone health tablets, and oral health lozenges. The Other segment includes packaging solutions and royalties from development projects. BioGaia's business model relies heavily on scientific validation, with its products backed by extensive clinical trials and marketed primarily through healthcare channels. The company distributes its products in over 100 countries across the EMEA, Americas, and APAC regions, utilizing a mix of local distribution partners, pharmaceutical companies, and its own direct-to-consumer operations.
